BUSINESS● LOWSep 29 · Sep 29, 2026, 9:00 AM
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
South China Morning Post · east asia
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS28m agoTaiwan Semiconductor Manufacturing Company declares NT$7.00 quarterly dividendSeeking Alpha TechBUSINESS29m agoAI job losses set to rein in office demand in developed Asia-Pacific economies: reportSouth China Morning Post